Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Novo Nordisk (NYSE:NVO) A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY).

Novo Nordisk reported Q2 and H1 FY22 results on 3rd August 2022.Excluding the effects of a strong US Dollar in 2022, results included a 14% year-over-year growth in Operating Profit, where ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, a leading global healthcare company, at the ...

Novo Nordisk A/S touted the potential of its next-generation obesity treatments, releasing promising data on an experimental daily pill and sending the shares soaring to a record.. A new treatment ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt after a series of trial results have left investors feeling unsatisfied.

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Stream Los Angeles News ...